Incyte (INCY) Invested Capital (2010 - 2026)
Incyte posted quarterly Invested Capital of $5.7 billion for Q1 2026, up 52.65% year-on-year from $3.7 billion in Q1 2025, and up 8.84% on a QoQ basis from $5.2 billion in Q4 2025.
Incyte (INCY) has 17 years of Invested Capital data on file, last reported at $5.7 billion in Q1 2026.
- For the quarter ending Q1 2026, Invested Capital rose 52.65% year-over-year to $5.7 billion; the trailing twelve-month figure through Mar 2026 stood at $5.7 billion (up 52.65% YoY), and the FY2025 full-year result was $5.2 billion, up 49.25% from the prior year.
- Invested Capital for Q1 2026 stood at $5.7 billion, up from $5.2 billion in the prior quarter.
- Across five years, Invested Capital topped out at $5.7 billion in Q1 2026 and bottomed at $3.0 billion in Q2 2024.
- The 5-year median for Invested Capital is $4.4 billion (2022), against an average of $4.4 billion.
- The widest annual swing landed in 2024, when Invested Capital plunged 36.5%; it then jumped 52.65% in 2026.
- A 5-year view of Invested Capital shows it stood at $4.4 billion in 2022, then gained by 18.6% to $5.2 billion in 2023, then slumped by 33.26% to $3.5 billion in 2024, then jumped by 49.25% to $5.2 billion in 2025, then climbed by 8.84% to $5.7 billion in 2026.
- The last three Invested Capital figures came in at $5.7 billion (Q1 2026), $5.2 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 595,226.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.08 Bn |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | 5.66 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.66 Bn |
| Dec 31, 2025 | 5.20 Bn |
| Sep 30, 2025 | 4.70 Bn |
| Jun 30, 2025 | 4.22 Bn |
| Mar 31, 2025 | 3.71 Bn |
| Dec 31, 2024 | 3.49 Bn |
| Sep 30, 2024 | 3.21 Bn |
| Jun 30, 2024 | 3.03 Bn |
| Mar 31, 2024 | 5.43 Bn |
| Dec 31, 2023 | 5.22 Bn |
| Sep 30, 2023 | 4.97 Bn |
| Jun 30, 2023 | 4.78 Bn |
| Mar 31, 2023 | 4.50 Bn |
| Dec 31, 2022 | 4.40 Bn |
| Sep 30, 2022 | 4.26 Bn |
| Jun 30, 2022 | 4.12 Bn |
| Mar 31, 2022 | 3.90 Bn |
| Dec 31, 2021 | 3.81 Bn |
| Sep 30, 2021 | 3.19 Bn |
| Jun 30, 2021 | 2.98 Bn |
| Mar 31, 2021 | 2.77 Bn |
| Dec 31, 2020 | 2.65 Bn |
| Sep 30, 2020 | 2.43 Bn |
| Jun 30, 2020 | 2.38 Bn |
| Mar 31, 2020 | 1.96 Bn |
| Dec 31, 2019 | 2.63 Bn |
| Sep 30, 2019 | 2.45 Bn |
| Jun 30, 2019 | 2.28 Bn |
| Mar 31, 2019 | 2.12 Bn |
| Dec 31, 2018 | 1.96 Bn |
| Sep 30, 2018 | 1.81 Bn |
| Jun 30, 2018 | 1.74 Bn |
| Mar 31, 2018 | 1.66 Bn |
| Dec 31, 2017 | 1.64 Bn |
| Sep 30, 2017 | 1.78 Bn |
| Jun 30, 2017 | 1.05 Bn |
| Mar 31, 2017 | 987.46 Mn |
| Dec 31, 2016 | 439.01 Mn |
| Sep 30, 2016 | 387.84 Mn |
| Jun 30, 2016 | 314.75 Mn |
| Mar 31, 2016 | 227.75 Mn |
| Dec 31, 2015 | 171.16 Mn |
| Sep 30, 2015 | 88.74 Mn |
| Jun 30, 2015 | 98.11 Mn |
| Mar 31, 2015 | 45.92 Mn |
| Dec 31, 2014 | 3.56 Mn |
| Sep 30, 2014 | -89.59 Mn |
| Jun 30, 2014 | -171.00 Mn |
| Mar 31, 2014 | -162.42 Mn |
| Dec 31, 2013 | -193.11 Mn |
| Sep 30, 2013 | 28.79 Mn |
| Jun 30, 2013 | -27.79 Mn |
| Mar 31, 2013 | -163.53 Mn |
| Dec 31, 2012 | -174.96 Mn |
| Sep 30, 2012 | -210.13 Mn |
| Jun 30, 2012 | -207.51 Mn |
| Mar 31, 2012 | -239.31 Mn |
| Dec 31, 2011 | -227.08 Mn |
| Sep 30, 2011 | -181.02 Mn |
| Jun 30, 2011 | -136.28 Mn |
| Mar 31, 2011 | -103.98 Mn |
| Dec 31, 2010 | -88.64 Mn |